Edwards Lifesciences Cash Flow from Operating Activities 2010-2025 | EW
Edwards Lifesciences annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Edwards Lifesciences cash flow from operating activities for the quarter ending March 31, 2025 was $0.542B, a 39.46% decline year-over-year.
- Edwards Lifesciences cash flow from operating activities for the twelve months ending March 31, 2025 was $1.477B, a 36.27% decline year-over-year.
- Edwards Lifesciences annual cash flow from operating activities for 2024 was $0.542B, a 39.46% decline from 2023.
- Edwards Lifesciences annual cash flow from operating activities for 2023 was $0.896B, a 26.47% decline from 2022.
- Edwards Lifesciences annual cash flow from operating activities for 2022 was $1.218B, a 29.67% decline from 2021.
| Edwards Lifesciences Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $542 |
| 2023 | $896 |
| 2022 | $1,218 |
| 2021 | $1,732 |
| 2020 | $1,054 |
| 2019 | $1,183 |
| 2018 | $927 |
| 2017 | $1,001 |
| 2016 | $704 |
| 2015 | $550 |
| 2014 | $1,022 |
| 2013 | $473 |
| 2012 | $362 |
| 2011 | $308 |
| 2010 | $251 |
| 2009 | $165 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $44.472B | $5.440B |
| Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. | |||